These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 22736481)

  • 41. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.
    Doi T; Muro K; Boku N; Yamada Y; Nishina T; Takiuchi H; Komatsu Y; Hamamoto Y; Ohno N; Fujita Y; Robson M; Ohtsu A
    J Clin Oncol; 2010 Apr; 28(11):1904-10. PubMed ID: 20231677
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.
    Reinisch W; Panés J; Lémann M; Schreiber S; Feagan B; Schmidt S; Sturniolo GC; Mikhailova T; Alexeeva O; Sanna L; Haas T; Korom S; Mayer H
    Am J Gastroenterol; 2008 Sep; 103(9):2284-92. PubMed ID: 18671816
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
    Druce MR; Kaltsas GA; Fraenkel M; Gross DJ; Grossman AB
    Horm Metab Res; 2009 Sep; 41(9):697-702. PubMed ID: 19424940
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience.
    De Filpo G; Cantini G; Rastrelli G; Vannini G; Ercolino T; Luconi M; Mannelli M; Maggi M; Canu L
    J Endocrinol Invest; 2022 Jan; 45(1):149-157. PubMed ID: 34227051
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients.
    Yao J; Wang JY; Liu Y; Wang B; Li YX; Zhang R; Wang LS; Liu L
    Med Oncol; 2014 Dec; 31(12):251. PubMed ID: 25395378
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcomes of pheochromocytoma management in the laparoscopic era.
    Solorzano CC; Lew JI; Wilhelm SM; Sumner W; Huang W; Wu W; Montano R; Sleeman D; Prinz RA
    Ann Surg Oncol; 2007 Oct; 14(10):3004-10. PubMed ID: 17690941
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
    Yao JC; Lombard-Bohas C; Baudin E; Kvols LK; Rougier P; Ruszniewski P; Hoosen S; St Peter J; Haas T; Lebwohl D; Van Cutsem E; Kulke MH; Hobday TJ; O'Dorisio TM; Shah MH; Cadiot G; Luppi G; Posey JA; Wiedenmann B
    J Clin Oncol; 2010 Jan; 28(1):69-76. PubMed ID: 19933912
    [TBL] [Abstract][Full Text] [Related]  

  • 48. N-Glycomic Profiling of Pheochromocytomas and Paragangliomas Separates Metastatic and Nonmetastatic Disease.
    Leijon H; Kaprio T; Heiskanen A; Satomaa T; Hiltunen JO; Miettinen MM; Arola J; Haglund C
    J Clin Endocrinol Metab; 2017 Nov; 102(11):3990-4000. PubMed ID: 28938401
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Everolimus plus octreotide long-acting repeatable in advanced neuroendocrine tumors in the routine tertiary cancer care setting: An Indian experience.
    Tippeswamy R; Patil S; Sateesh CT; Shashidhara HP; Prabhudesai S; Prashanth P; Haridas KM
    Indian J Cancer; 2015; 52(3):359-62. PubMed ID: 26905137
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PCSK2 expression in neuroendocrine tumors points to a midgut, pulmonary, or pheochromocytoma-paraganglioma origin.
    Remes SM; Leijon H; Vesterinen T; Louhimo J; Pulkkinen V; Ezer S; Kere J; Haglund C; Arola J
    APMIS; 2020 Nov; 128(11):563-572. PubMed ID: 32794589
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies.
    Santarpia L; Habra MA; Jiménez C
    Horm Metab Res; 2009 Sep; 41(9):680-6. PubMed ID: 19343618
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.
    O'Kane GM; Ezzat S; Joshua AM; Bourdeau I; Leibowitz-Amit R; Olney HJ; Krzyzanowska M; Reuther D; Chin S; Wang L; Brooks K; Hansen AR; Asa SL; Knox JJ
    Br J Cancer; 2019 Jun; 120(12):1113-1119. PubMed ID: 31105270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
    Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
    Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Controlling Tumor Progression with Cyclophosphamide, Vincristine, and Dacarbazine Treatment Improves Survival in Patients with Metastatic and Unresectable Malignant Pheochromocytomas/Paragangliomas.
    Asai S; Katabami T; Tsuiki M; Tanaka Y; Naruse M
    Horm Cancer; 2017 Apr; 8(2):108-118. PubMed ID: 28108930
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience.
    Ayala-Ramirez M; Feng L; Habra MA; Rich T; Dickson PV; Perrier N; Phan A; Waguespack S; Patel S; Jimenez C
    Cancer; 2012 Jun; 118(11):2804-12. PubMed ID: 22006217
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma.
    Kong G; Grozinsky-Glasberg S; Hofman MS; Callahan J; Meirovitz A; Maimon O; Pattison DA; Gross DJ; Hicks RJ
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3278-3287. PubMed ID: 28605448
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Histopathology, cytology and cytochemistry of pheochromocytomas and paragangliomas including chemodectomas.
    Capella C; Riva C; Cornaggia M; Chiaravalli AM; Frigerio B; Solcia E
    Pathol Res Pract; 1988 Apr; 183(2):176-87. PubMed ID: 2838831
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Image cytometric nuclear DNA quantitation of paragangliomas in tissue sections. Prognostic significance.
    Held EL; Gal AA; DeRose PB; Cohen C
    Anal Quant Cytol Histol; 1997 Dec; 19(6):501-6. PubMed ID: 9893904
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients with Metastatic Pheochromocytomas/Paragangliomas.
    Zhou Y; Cui Y; Zhang D; Tong A
    J Clin Endocrinol Metab; 2023 Feb; 108(3):755-766. PubMed ID: 36383456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.